FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Senators Have More Software Pre-Cert Questions

[ Price : $8.95]

Sens. Warren, Murray, and Smith raise 18 additional questions for FDA to answer on its software pre-certification program.

GDUFA 2 User Fee Assessment

[ Price : $8.95]

FDA issues a draft guidance on changes affecting its implementation of GDUFA 2 user fees.

Genentech BLA Submitted for Satralizumab

[ Price : $8.95]

FDA accepts for review a Genentech BLA for satralizumab for treating adults and adolescents with neuromyelitis optica spectrum dis...

Developing Drugs for Hepatitis D Virus Infection

[ Price : $8.95]

FDA publishes a draft guidance to assist sponsors develop drugs to treat hepatitis D virus infection.

Meeting on Health Equity Related to Opioid Crisis

[ Price : $8.95]

Federal Register notice: FDA announces an 11/21 public meeting entitled Office of Minority Health and Health Equity Public Meeting...

FDA Credits 2019 Cybersecurity Work

[ Price : $8.95]

FDA lists six of its 2019 activities to promote medical device cybersecurity safety and awareness.

Shreis Wins Breakthrough for Tissue Control Device

[ Price : $8.95]

FDA grants Shreis Scalene Sciences a Breakthrough Device designation for Cytotron, a whole-body therapeutic medical device for use...

FDA Grants Recro Meloxicam Appeal

[ Price : $8.95]

FDA grants Recro Pharmas appeal of an agency complete response letter for the firms IV meloxicam.

ICU Medical Recalls 2 Products Over Particulate Matter

[ Price : $8.95]

ICU Medical recalls one single lot of lactated ringers injection, USP, and one single lot of 0.9% sodium chloride injection, USP, ...

CARsgen Gains Regenerative Medicine Advanced Therapy Status

[ Price : $8.95]

FDA grants CARsgen Therapeutics a Regenerative Medicine Advanced Therapy designation for its investigational CT053 CAR-T cell ther...